Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TYRAthis companyTyra Biosciences, Inc.	$21.76	-13.08×	6.05×	0×	-12.52×	-94.5%	0.0%	0.0%	0.0%	-46.3%	-50.1%	-6.1%	0.02×	0.6×	0×	14.67×	0.0%	1	23.84	2	C
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
BCAXBicara Therapeutics Inc. Common Stock	$8.99	-6.68×	2.29×	0×	-6×	-79.8%	0.0%	0.0%	0.0%	-34.4%	-38.6%	-11.6%	0×	0.69×	0×	14.58×	0.0%	1	5.84	2	C+
CGEMCullinan Therapeutics, Inc.	$11.71	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
JANXJanux Therapeutics, Inc.	$14.14	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
Peer median	—	-4.66×	1.5×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-34.4%	-57.8%	-20.8%	0×	0.39×	0×	12.83×	0.0%	2	8.27	2	—